Chiesi Ventures

About The Fund

Chiesi Ventures is a venture capital firm and a capital arm of Chiesi Farmaceutici, primarily focused on funding innovation in rare and orphan disorders. Established in 2014 and based in Boston, Massachusetts, with regional offices in Parma, Italy, and Durham, North Carolina, they aim to foster early-stage development opportunities that align with the strategic interests of the Chiesi Group. Their investment activities span across seed to early-stage companies in the healthcare, life sciences, pharmaceutical, and health technology sectors. Their investment thesis emphasizes on small molecules and biologics, advanced therapies, reformulation, technological platforms and devices, as well as disease discovery, diagnosis, and management. Chiesi Ventures’ goal is to improve the quality of diagnosis, disease management, care, and therapy for patients with rare diseases. By creating a portfolio of companies with specific but complementary capabilities, they strive to address the significant therapeutic need in the field of rare diseases, which collectively affect 30 million people in Europe, with a similar prevalence in the US. The fund invests between $12,000,000 to $30,000,000 in entities that share this commitment. Their strategic collaboration with Pappas Capital empowers them to leverage expertise and a network to access deals and manage transactions effectively. Through such partnerships and their presence in the US and EU, Chiesi Ventures actively engages in dialogue with researchers, the scientific community, industry, regulators, and rare disease patient organizations, supporting a global approach in the understanding and treatment of rare diseases.